GlassScriptPhysician profile
Jonathan W Biggers
NPI 1184038705
$1,765.06
in general payments reported to CMS, 2019-2025
11 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $129 · 2021: $218 · 2023: $257 · 2024: $372 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $456.54 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Abbvie INC. | $379.45 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $271.80 | 2021-2025 | Wegovy |
| Pfizer INC. | $214.60 | 2024-2025 | |
| Lilly USA, LLC | $162.34 | 2024-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $121.92 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $45.93 | 2020-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.15 | 2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $29.37 | 2024-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $27.85 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $23.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Biggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.